Robert Earl Webster

Address:

295 Richbriar St, Memphis, TN 38120

Phone:

9016829889

VIN:

1HGCP3F88BA025055

Make:

HONDA

Model:

ACCORD

Year:

2011

US Patent:

6344354, Feb 5, 2002

Filed:

Jun 16, 1998

Appl. No.:

09/097712

Inventors:

Robert G. Webster - Memphis TN
Nicolai V. Kaverin - Moscow, RU

Assignee:

St. Jude Childrens Research Hospital - Memphis TN

International Classification:

C12N 700

US Classification:

4352351, 424 936, 4242061, 4242091, 435236, 435239

Abstract:

The invention provides replication of high growth influenza virus strains, derived from clinical isolates, in cultured mammalian cells by infecting the mammalian cells with the high growth strains to obtain infected cells, and culturing the cells while maintaining a trypsin concentration range of 0. 05-1. 0 g/ml in the culture medium, where the resulting replicated virus is suitable for use in mammalian influenza vaccines and vaccination methods, which are also provided by the invention.

US Patent:

6841381, Jan 11, 2005

Filed:

Jan 27, 1994

Appl. No.:

08/187879

Inventors:

Harriet L. Robinson - Southboro MA, US
Ellen F. Fynan - Sterling MA, US
Robert G. Webster - Memphis TN, US
Shan Lu - Northboro MA, US

Assignee:

University of Massachusetts Medical Center - Worcester MA
St. Jude Children's Research Hospital - Memphis TN

International Classification:

C12N 1563
C12N 1500

US Classification:

4353201, 435 691, 435325, 435455

Abstract:

This invention relates to a method of immunizing a vertebrate, comprising introducing into the vertebrate a DNA transcription unit which comprises DNA encoding a desired antigen or antigens. The uptake of the DNA transcription unit by a host vertebrate results in the expression of the desired antigen or antigens, thereby eliciting humoral or cell-mediated immune responses or both humoral and cell-mediated responses. The elicited humoral and cell-mediated immune response can provide protection against infection by pathogenic agents, provide an anti-tumor response, or provide contraception. The host can be any vertebrate, avian or mammal, including humans.

US Patent:

7037707, May 2, 2006

Filed:

Sep 4, 2003

Appl. No.:

10/654737

Inventors:

Robert Gordon Webster - Memphis TN, US
Richard John Webby - Memphis TN, US
Hiroichi Ozaki - Memphis TN, US

Assignee:

St. Jude Children's Research Hospital - Memphis TN

International Classification:

C12N 7/00
C12Q 1/70
A01N 63/00

US Classification:

4352351, 435 5, 4353201, 424 936, 4242061, 930220

Abstract:

The present invention is based on the discovery that a high titer reassortant influenza virus is produced in mammalian cell culture by replacing the NS gene of the A/PuertoRico/3/24 master strain with the NS gene of the A/England/1/53 strain. The invention provides influenza viruses and vaccines generated in mammalian cells as well as methods for producing such. The invention further provides an influenza virus master strain and kits for generating reassortant influenza viruses in mammalian cell culture and methods of making and using the master strain.

US Patent:

7850956, Dec 14, 2010

Filed:

Jan 22, 2004

Appl. No.:

10/763049

Inventors:

Harriet L. Robinson - Atlanta GA, US
Ellen F. Fynan - Sterling MA, US
Robert G. Webster - Memphis TN, US
Shan Lu - Franklin MA, US

Assignee:

University of Massachusetts Medical Center - Worcester MA
St. Jude Children's Research Hospital - Memphis TN

International Classification:

A61K 48/00
A61K 39/12

US Classification:

424 932, 514 44, 4241861

Abstract:

This invention relates to a method of immunizing a vertebrate, comprising introducing into the vertebrate a DNA transcription unit which comprises DNA encoding a desired antigen or antigens. The uptake of the DNA transcription unit by a host vertebrate results in the expression of the desired antigen or antigens, thereby eliciting humoral or cell-mediated immune responses or both humoral and cell-mediated responses. The elicited humoral and cell-mediated immune response can provide protection against infection by pathogenic agents, provide an anti-tumor response, or provide contraception. The host can be any vertebrate, avian or mammal, including humans.

US Patent:

7871626, Jan 18, 2011

Filed:

Jul 27, 2006

Appl. No.:

11/460584

Inventors:

Erich Hoffmann - Memphis TN, US
Aleksandr S. Lipatov - Bartlett TN, US
Richard J. Webby - Memphis TN, US
Elena A. Govorkova - Cordova TN, US
Robert G. Webster - Memphis TN, US

Assignee:

St. Jude Children's Research Hospital - Memphis TN

International Classification:

A61K 39/145
A61K 39/12
A61K 39/00
A01N 63/00
C12Q 1/70
C12P 21/06
C07K 14/00
A61K 39/245

US Classification:

4242061, 4242051, 4241991, 4241861, 4241851, 4242091, 424 936, 435 5, 435 691, 530350

Abstract:

The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.

US Patent:

8124101, Feb 28, 2012

Filed:

Jun 1, 2005

Appl. No.:

11/628292

Inventors:

Peter Palese - Leonia NJ, US
Adolfo Garcia-Sastre - New York NY, US
Richard J. Webby - Memphis TN, US
Juergen A. Richt - Ames IA, US
Robert G. Webster - Memphis TN, US
Kelly M. Lager - Colo IA, US

Assignee:

Mount Sinai School of Medicine - New York NY
St. Jude Children's Research Hospital - Memphis TN
The United States of America as represented by The Secretary of Agriculture - Washington DC

International Classification:

A61K 39/145
A61K 49/00

US Classification:

4242061, 4242091, 424 92

Abstract:

The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

US Patent:

8293247, Oct 23, 2012

Filed:

Dec 9, 2010

Appl. No.:

12/964491

Inventors:

Erich Hoffmann - Galveston TX, US
Aleksandr S. Lipatov - Atlanta GA, US
Richard J. Webby - Memphis TN, US
Elena A. Govorkova - Cordova TN, US
Robert G. Webster - Memphis TN, US

Assignee:

St. Jude Children's Research Hospital - Memphis TN

International Classification:

A61K 39/145

US Classification:

4242061, 4242051, 4241991, 4241881, 4241851, 4242091, 424 936, 435 5, 435 691, 530350

Abstract:

The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.

US Patent:

8574592, Nov 5, 2013

Filed:

Sep 13, 2012

Appl. No.:

13/614835

Inventors:

Erich Hoffmann - Galveston TX, US
Aleksandr S. Lipatov - Atlanta GA, US
Richard J. Webby - Memphis TN, US
Elena A. Govorkova - Cordova TN, US
Robert G. Webster - Memphis TN, US

Assignee:

St. Jude Children's Research Hospital - Memphis TN

International Classification:

A61K 39/145
A61K 39/12
A61K 39/00
A01N 63/00
C12Q 1/70
C12P 21/06
C07K 14/00

US Classification:

4242061, 4242051, 4241991, 4241861, 4241851, 4242091, 424 936, 435 5, 435 691, 530350

Abstract:

The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.